ADCC	Antibody-dependent Cellular Cytotoxicity
AEs	Any-Grade Adverse Events
ALL	Acute Lymphoblastic Leukemia
AML	Acute Myeloid Leukemia
AP1	Activator Protein 1
APCs	Antigen-presenting Cells
ASCT	Autologous Stem Cell Transplantation
B-ALL	B-cell acute lymphoblastic lymphoma
BCMA	B-Cell Maturation Antigen
BM	Bone Marrow
CAR	Chimeric Antigen Receptors
cilta-cel	Ciltacabtagene Autoleucel
CI	Confidence Interval
CRS	Cytokine Release Syndrome
DLBCL	Diffuse Large B-Cell Lymphoma
FDA	Food and Drug Administration
FKBP	FK506 Binding Protein
GBM	glioblastoma multiforme
GPRC5D	G-Protein Coupled Receptor Family C Group 5 Member D
iCasp9	inducible Caspase 9
ide-cel	Idecabtagene Vicleucel
IMiD	Immunomodulatory Drugs
iCARs	Inhibitory CARs
IFN-γ	Interferon Gamma
IL	Interleukin
IMWG	International Myeloma Working Group
LAG3	Lymphocyte Activating 3
MM	Multiple Myeloma
MRD	Measurable Residual Disease
NF-κB	Nuclear Factor Kappa-B
ORR	Overall Response Rate
OS	Overall Survival
PC	Plasma Cell
PD-1	Programmed Cell Death Protein 1
PFS	Progression-Free Survival
PI	Proteasome Inhibitors
RRMM	Relapsed and/or Refractory Multiple Myeloma
SEMA4A	Semaphorin-4A
SLAMF7	Signaling Lymphocyte Activation Molecule F7
scFv	Single-Chain Variable Fragment
sBCMA	Soluble B-Cell Maturation Antigen
sCR	Stringent Complete Response
STAT5	Signal Transducer and Activator of Transcription 5
TCR	T-cell Receptor
TRUCK	T-cells Redirected for Universal Cytokine Killing
TGF-β	Transforming Growth Factor-beta
TME	Tumor Microenvironment
TNF-α	Tumor Necrosis Factor-Alpha
VGPR	Very Good Partial Response